Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives.

45 The data also suggested an improvement in patients’ mental health, as a numerically greater proportion of the secukinumab 150 mg group versus the placebo group had clinically meaningful improvements in SF-36 MCS at Week 16 (53.7% versus 47.9%), but this difference did not reach statistical significance. 45 These improvements were consistent in patients who were anti-TNF-naïve and those who were anti-TNF-IR, although responses were more prominent in anti-TNF-naïve patients.

also in 111,027 other papers